DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results for the second quarter ended June 30, 2007, reporting a net loss of $5.9 million, or ($0.14) per share. Total revenue for the second quarter of 2007 was $15.4 million, as compared to $13.4 million for the second quarter of 2006. Co-promotion revenue from net sales of Elestat® (epinastine HCl ophthalmic solution) 0.05% for the second quarter of 2007 was $9.7 million, a 3% increase compared to $9.4 million recognized in the second quarter of 2006. The Company achieved its 2007 net sales target level for Elestat in the second quarter and recognized $2.4 million of previously deferred revenue on net sales of Elestat. Co-promotion revenue on net sales of Restasis® (cyclosporine ophthalmic emulsion) 0.05% for the second quarter of 2007 was $5.7 million, a 41% increase compared to $4.0 million recognized in the second quarter of 2006.
